Literature DB >> 25424984

Rapid and sensitive ultra-high-pressure liquid chromatography method for quantification of antichagasic benznidazole in plasma: application in a preclinical pharmacokinetic study.

Marcelo Gomes Davanço1, Michel Leandro de Campos1, Rosângela Gonçalves Peccinini1.   

Abstract

Benznidazole (BNZ) and nifurtimox are the only drugs available for treating Chagas disease. In this work, we validated a bioanalytical method for the quantification of BNZ in plasma aimed at improving sensitivity and time of analysis compared with the assays already published. Furthermore, we demonstrated the application of the method in a preclinical pharmacokinetic study after administration of a single oral dose of BNZ in Wistar rats. A Waters® Acquity UHPLC system equipped with a UV-vis detector was employed. The method was established using an Acquity® UHPLC HSS SB C18 protected by an Acquity® UHPLC HSS SB C18 VanGuard guard column and detection at 324 nm. The mobile phase consisted of ultrapure water-acetonitrile (65:35), and elution was isocratic. The mobile phase flow rate was 0.55 mL/min, the volume of injection was 1 μL, and the run time was just 2 min. The samples were kept at 25°C until injection and the column at 45°C for the chromatographic separation. The sample preparation was performed by a rapid protein precipitation with acetonitrile. The linear concentration range was 0.15-20 µg/mL. The pharmacokinetic parameters of BNZ in rats were determined and the method was considered sensitive, fast and suitable for application in pharmacokinetic studies.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Chagas disease; benznidazole; bioanalytical method; pharmacokinetic parameters; ultra-high pressure liquid chromatography; validation method

Mesh:

Substances:

Year:  2014        PMID: 25424984     DOI: 10.1002/bmc.3386

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  5 in total

1.  Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.

Authors:  Suzana Marques de Jesus; Leonardo Pinto; Fernanda de Lima Moreira; Glauco Henrique Balthazar Nardotto; Rodrigo Cristofoletti; Luísa Perin; Kátia da Silva Fonseca; Pauliana Barbêdo; Lorena Cera Bandeira; Paula Melo de Abreu Vieira; Claudia Martins Carneiro
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice.

Authors:  Luísa Perin; Rodrigo Moreira da Silva; Kátia da Silva Fonseca; Jamille Mirelle de Oliveira Cardoso; Fernando Augusto Siqueira Mathias; Levi Eduardo Soares Reis; Israel Molina; Rodrigo Correa-Oliveira; Paula Melo de Abreu Vieira; Cláudia Martins Carneiro
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Benznidazole Extended-Release Tablets for Improved Treatment of Chagas Disease: Preclinical Pharmacokinetic Study.

Authors:  Marcelo Gomes Davanço; Michel Leandro Campos; Talita Atanazio Rosa; Elias Carvalho Padilha; Alejandro Henao Alzate; Larissa Araújo Rolim; Pedro José Rolim-Neto; Rosângela Gonçalves Peccinini
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

4.  Hepatic changes by benznidazole in a specific treatment for Chagas disease.

Authors:  Tycha Bianca Sabaini Pavan; Jamiro Wanderley da Silva; Luiz Cláudio Martins; Sandra Cecília Botelho Costa; Eros Antônio de Almeida
Journal:  PLoS One       Date:  2018-07-20       Impact factor: 3.240

5.  Dried Blood Spot Technique-Based Liquid Chromatography-Tandem Mass Spectrometry Method as a Simple Alternative for Benznidazole Pharmacokinetic Assessment.

Authors:  Danilo César Galindo Bedor; Noely Camila Tavares Cavalcanti Bedor; José Wellithom Viturino da Silva; Giovana Damasceno Sousa; Davi Pereira de Santana; Facundo Garcia-Bournissen; Jaime Altcheh; Bethania Blum; Fabiana Alves; Isabela Ribeiro
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.